Sixth Wave’s patent-pending solution provides several advantages for detecting, containing, and, ultimately, ending viral pandemics, such as SARS-CoV-2. Unlike other Polymerase Chain Reaction (PCR) and Immunoassay diagnostic tests, the AMIPs system directly detects viral particles rather than antibodies or antigens that can take days or weeks to be detectable within a patient. Impressively, AMIPs can also identify specific components such as viral DNA, RNA, proteins, small molecules, and even antibodies, making it one of the most versatile testing solutions to date.
Because the technology is based on a cartridge design, Sixth Wave believes the development of AMIPs detection for new viral threats could take less than 30 days from the onset, as well as, allow screening for multiple classes of viruses. the spread of future outbreaks could be contained much earlier with Sixth Wave’s solution.
Finally, the platform is infinitely scalable and adaptable. The AMIPs technology allows Sixth Wave to configure the test to screen for multiple infections at once. By detecting classes of viruses, researchers can deploy new diagnostics without cultivating antigens or collecting antibodies in the case of novel viruses, like coronavirus.